Clinical Trial

A Single-Arm Interventional Trial of Pepper- Robot Delivered Cancer Education for Adults With Intellectual Disability

Study acronym: Pep-SMARTID
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 17, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Individuals with Intellectual disability face numerous barriers to cancer education, awareness and screening, including communication challenges, anxiety, and a lack of accessible educational resources. Traditional methods often fail to meet their unique learning needs, contributing to lower screening rates , delayed diagnoses and poorer outcomes.. Socially assistive robots, have demonstrated effectiveness in delivering interactive, engaging, and tailored education, helping individuals with cognitive impairments better understand medical procedures and the importance of preventive care. The study investigators propose to conduct a pilot single arm clinical trial with a semi humanoid robot to deliver cancer awareness education to adults with intellectual disability attending a disability day service in Ireland .The semi humanoid robot will be programmed to engage in 2 way communication about the cancer related educational content that is uploaded on its system. .Approximately 25 adults with ID will receive the robot led educational intervention addressing both breast and colorectal cancer awareness and screening. This a pragmatic pilot study to inform a future larger controlled clinical trial Our overall objective is to Improve breast and colorectal cancer awareness knowledge level among adults with ID receiving a robot-delivered education intervention
Trial Details
NCT Number NCT07477938
Lead Sponsor National University of Ireland, Galway, Ireland
Collaborators: Brothers of Charity Services Galway Ireland, University College Hospital Galway
Conditions Cancer Awareness and Prevention Education, Breast Cancer Awareness, Intellectual Disabilities (F70-F79)
Enrollment 25 participants
Start Date 2026-05-01
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-17